Pfizer Downgraded to “Hold” at UBS AG (PFE)
Pfizer (NYSE:PFE) was downgraded by investment analysts at UBS AG from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Analyst Ratings Network.com reports.
Shares of Pfizer (NYSE:PFE) traded down 0.65% during mid-day trading on Thursday, hitting $30.75. The stock had a trading volume of 8,274,935 shares. Pfizer has a one year low of $26.19 and a one year high of $32.50. The stock’s 50-day moving average is $31.03 and its 200-day moving average is $29.64. The company has a market cap of $199.3 billion and a P/E ratio of 8.54.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The company reported $0.58 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.56 by $0.02. The company had revenue of $12.64 billion for the quarter, compared to the consensus estimate of $12.69 billion. During the same quarter in the prior year, the company posted $0.53 earnings per share. The company’s quarterly revenue was down 2.4% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.18 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, March 4th. Investors of record on Friday, February 7th will be given a dividend of 0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date of this dividend is Wednesday, February 5th. This is an increase from Pfizer’s previous quarterly dividend of $0.24.
PFE has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Pfizer from $31.00 to $33.00 in a research note to investors on Thursday. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note to investors on Tuesday. They now have a $32.00 price target on the stock. Finally, analysts at Cowen and Company cut their price target on shares of Pfizer from $37.00 to $34.00 in a research note to investors on Monday, December 30th. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $31.78.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.